This page may have documents that can’t be read by screen reader software. For help with these documents, please call 1-800-975-6314.
Applies to Group and Retail
As you’re aware, the federal government released guidance this week about coverage of over-the-counter (OTC) COVID-19 diagnostic tests.
Some key highlights:
What this means to you: BCBSIL will cover COVID-19 diagnostic OTC tests through our extensive network of participating pharmacies, for our fully insured members, and self-insured group members who have Prime Therapeutics® coverage through BCBSIL.
Members can use the same broad networks used for COVID-19 vaccines to request tests. Claims will be submitted directly from the pharmacy to BCBSIL.
In-network locations include:
Self-insured customer approach:
For our self-insured customers who use BCBSIL and Prime Therapeutics to administer their pharmacy benefit, here's our approach:
Our self-insured customers who have their pharmacy benefits carved-out will need to confirm how their carved-out PBM is managing COVID-19 diagnostic OTC testing.
While we provide information about federal guidance, we do not provide groups with legal or compliance advice. Group customers must contact their legal advisors if they have questions about proposed rules and new regulations, what they will require and how they will affect their benefit plans if finalized.
This information applies to members and groups with prescription drug benefits administered through Blue Cross and Blue Shield of Illinois (BCBSIL).
BCBSIL contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. In addition, contracting pharmacies are contracted through Prime Therapeutics. The relationship between BCBSIL and contracting pharmacies is that of independent contractors. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.